| Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade | Cellular and molecular life sciences |  | | 2025 | 197 | 166 |
|
| PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma | Cancer immunology research | | | 2024 | 312 | 379 |
|
| Radio-chemotherapy of glioblastoma cells promotes phagocytosis by macrophages in vitro | Radiotherapy and oncology | | | 2024 | 122 | 70 |
|
| Combining antimiR-25 and cGAMP Nanocomplexes Enhances Immune Responses via M2 Macrophage Reprogramming | International journal of molecular sciences | | | 2024 | 116 | 257 |
|
| Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages | Cell communication and signaling | | | 2024 | 147 | 85 |
|
| Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy | Clinical and Experimental Medicine | | | 2024 | 111 | 59 |
|
| How to outsmart the cold tumor microenvironment: Design of STING ligand nanoparticles for improved cancer immunotherapy | OpenNano | | | 2023 | 88 | 51 |
|
| Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma | Cell death and disease | | | 2023 | 335 | 292 |
|
| Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition | Neuro-oncology | | | 2022 | 297 | 179 |
|
| Synthesis, Formulation and Characterization of Immunotherapeutic Glycosylated Dendrimer/cGAMP Complexes for CD206 Targeted Delivery to M2 Macrophages in Cold Tumors | Pharmaceutics | | | 2022 | 262 | 123 |
|
| An update on actively targeted liposomes in advanced drug delivery to glioma | International journal of pharmaceutics |  | | 2021 | 200 | 1 |
|
| Glioma-Derived Extracellular Vesicles - Far More Than Local Mediators | Frontiers in immunology | | | 2021 | 223 | 549 |
|
| Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma | Journal for immunotherapy of cancer | | | 2021 | 286 | 414 |
|
| Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin) | JCI insight | | | 2021 | 271 | 412 |
|
| Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells | Communications Biology | | | 2021 | 354 | 254 |
|
| An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin | Biology (Basel)[2079-7737] | | | 2020 | 494 | 357 |
|
| Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer | Journal of Controlled Release | | | 2020 | 297 | 367 |
|
| Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review | Journal for immunotherapy of cancer | | | 2020 | 211 | 478 |
|
| Harnessing Microglia and Macrophages for the Treatment of Glioblastoma | Frontiers in Pharmacology | | | 2019 | 474 | 399 |
|
| Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine | JCI Insight | | | 2019 | 317 | 3 |
|
| Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients | Neuro-Oncology | | | 2019 | 864 | 932 |
|
| Peptides as cancer vaccines | Current Opinion in Pharmacology | | | 2019 | 433 | 4 |
|
| Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models | OncoImmunology | | | 2018 | 442 | 1 |
|
| Let there be oxygen and T cells | Journal of Clinical Investigation | | | 2018 | 403 | 207 |
|
| Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines | Cellular and Molecular Life Sciences | | | 2018 | 407 | 225 |
|
| Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma | OncoImmunology | | | 2018 | 676 | 459 |
|
| Immunothérapie des gliomes : illusion ou espoir ? | Bulletin du cancer | | | 2017 | 437 | 0 |
|
| Identification of a novel population of highly cytotoxic c-Met-expressing CD8(+) T lymphocytes | EMBO Reports | | | 2017 | 607 | 4 |
|
| ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells | EMBO Journal | | | 2017 | 634 | 10 |
|
| Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? | Frontiers in Oncology | | | 2016 | 545 | 501 |
|
| Cell-penetrating peptides-the Swiss Army knife of cancer vaccines | Oncoimmunology | | | 2016 | 663 | 396 |
|
| Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes | PloS one | | | 2016 | 593 | 333 |
|
| Hypoxia and antitumor CD8(+) T cells: An incompatible alliance? | OncoImmunology | | | 2016 | 501 | 429 |
|
| Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing | PloS one | | | 2016 | 681 | 737 |
|
| Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants | Molecular therapy | | | 2016 | 693 | 437 |
|
| Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells | European Journal of Immunology | | | 2015 | 564 | 7 |
|
| Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity | Cancer research | | | 2015 | 657 | 10 |
|
| Immunotherapy of Brain Tumors | Progress in tumor research | | | 2015 | 599 | 0 |
|
| The CD40/CD40L axis in glioma progression and therapy | Neuro-oncology | | | 2015 | 511 | 264 |
|
| Immunotherapy for glioma: from illusion to realistic prospects? | American Society of Clinical Oncology educational book | | | 2014 | 1,289 | 691 |
|
| Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours | PloS one | | | 2013 | 752 | 345 |
|
| The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity | Journal of neuroinflammation | | | 2013 | 642 | 421 |
|
| Getting by with a little help from the right CD4+ T cells | Oncoimmunology | | | 2013 | 600 | 301 |
|
| Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapies | Immunotherapy |  | | 2013 | 559 | 0 |
|
| Macrophages and Microglia in Brain Malignancies | Tumor Microenvironment and Myelomonocytic Cells | | | 2012 | 549 | 762 |
|
| Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy | Brain | | | 2012 | 725 | 1,853 |
|
| Oncology ESAB 2011 | | | | 2011 | 697 | 10 |
|
| Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development | Cancer research | | | 2010 | 636 | 3 |
|
| T-cell immunotherapy for malignant glioma: toward a combined approach | Current opinion in oncology | | | 2010 | 678 | 2 |
|
| Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes | GLIA | | | 2008 | 675 | 11 |
|
